Treatment of cancer associated anaemia

Janusz Rolski; Marek Pawlicki

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2001
vol. 5

Send email

Copy url:

abstract:

Treatment of cancer associated anaemia

Janusz Rolski

,

Marek Pawlicki

Współcz Onkol (2001) vol. 5, 5 (222-225)

Online publish date: 2003/11/18

View full text Get citation

Cancer associated anaemia is reported in 50% of cancer patients and life threating anaemia (Hb <6 g/dl) is observed in 8% of such patients. Etiopathogenesis of cancer associated anaemia was presented as well as early and late toxicity of blood transfusion. Erythropoietin treatment seems to be justified due to evident data suggesting quality of life and clinical response improvement related to anaemia cancer associated therapy. The most of patients respond to erythropoietin treatment and its cost are comparable with blood transfusions and post-transfusion toxicity treatment cost.

keywords:

Treatment of cancer associated anaemia

Janusz Rolski , Marek Pawlicki

anaemia, erythropoietin, malignant neoplasms, treatment cost, post-transfusion toxicity

Janusz Rolski

,

Marek Pawlicki